MedPath

Shenzhen Geno-Immune Medical Institute

Ownership
Private
Established
2015-04-28
Employees
-
Market Cap
-
Website

GD2/CD70 Bi-specific CAR-T Cell Therapy

Phase 1
Recruiting
Conditions
Cancer Disease
First Posted Date
2022-06-30
Last Posted Date
2022-06-30
Lead Sponsor
Shenzhen Geno-Immune Medical Institute
Target Recruit Count
30
Registration Number
NCT05438368
Locations
🇨🇳

Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

GD2/PSMA Bi-specific CAR-T Cell Therapy

Phase 1
Recruiting
Conditions
Solid Tumor
First Posted Date
2022-06-29
Last Posted Date
2022-06-29
Lead Sponsor
Shenzhen Geno-Immune Medical Institute
Target Recruit Count
60
Registration Number
NCT05437315
Locations
🇨🇳

Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

CD19/79b Bi-specific CAR-T Cell Therapy

Phase 1
Recruiting
Conditions
B Cell Malignancies
First Posted Date
2022-06-29
Last Posted Date
2022-06-29
Lead Sponsor
Shenzhen Geno-Immune Medical Institute
Target Recruit Count
60
Registration Number
NCT05436509
Locations
🇨🇳

Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

PSMA/CD70 Bi-specific CAR-T Cell Therapy

Phase 1
Recruiting
Conditions
Cancer Disease
First Posted Date
2022-06-29
Last Posted Date
2022-06-29
Lead Sponsor
Shenzhen Geno-Immune Medical Institute
Target Recruit Count
60
Registration Number
NCT05437341
Locations
🇨🇳

Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

GD2/CD56 Bi-specific CAR-T Cell Therapy

Phase 1
Recruiting
Conditions
Malignant Disease
First Posted Date
2022-06-29
Last Posted Date
2022-06-29
Lead Sponsor
Shenzhen Geno-Immune Medical Institute
Target Recruit Count
60
Registration Number
NCT05437328
Locations
🇨🇳

Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

CD19/70 Bi-specific CAR-T Cell Therapy

Phase 1
Recruiting
Conditions
B Cell Malignancies
First Posted Date
2022-06-29
Last Posted Date
2022-06-29
Lead Sponsor
Shenzhen Geno-Immune Medical Institute
Target Recruit Count
30
Registration Number
NCT05436496
Locations
🇨🇳

Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

CD19/22 Bi-specific CAR-T Cell Therapy

Phase 1
Recruiting
Conditions
B Cell Malignancies
First Posted Date
2022-06-27
Last Posted Date
2022-06-27
Lead Sponsor
Shenzhen Geno-Immune Medical Institute
Target Recruit Count
60
Registration Number
NCT05432882
Locations
🇨🇳

Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL

Phase 1
Recruiting
Conditions
T-Cell Acute Lymphoblastic Leukemia
First Posted Date
2022-03-14
Last Posted Date
2022-03-15
Lead Sponsor
Shenzhen Geno-Immune Medical Institute
Target Recruit Count
10
Registration Number
NCT05277753
Locations
🇨🇳

Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL

Phase 1
Recruiting
Conditions
B-Cell Acute Lymphoblastic Leukemia
First Posted Date
2022-03-02
Last Posted Date
2022-03-08
Lead Sponsor
Shenzhen Geno-Immune Medical Institute
Target Recruit Count
10
Registration Number
NCT05262673
Locations
🇨🇳

Shenzhen Geno-Immune Medical Institute, Shenzhen, Guangdong, China

4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma

Phase 1
Conditions
Neuroblastoma
First Posted Date
2020-11-19
Last Posted Date
2020-11-19
Lead Sponsor
Shenzhen Geno-Immune Medical Institute
Target Recruit Count
100
Registration Number
NCT04637503
Locations
🇨🇳

Guangdong Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China

🇨🇳

Shenzhen Children's Hospital, Shenzhen, Guangdong, China

🇨🇳

Shenzhen Geno-Immune Medical Institute, Shenzhen, Guangzhou, China

and more 1 locations
© Copyright 2025. All Rights Reserved by MedPath